Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 12/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | POLG | P54098 | 2/20 | 0.57 |
| ▸ | POLA1 | P09884 | 1/20 | 0.57 |
| ▸ | PNP | P00491 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrophosphoric Acid SCHEMBL15054286 | 1.00 | HPRT1 (0.66) | HPRT1POLBCYP3A4POLGPOLA1 | |
| Pyrophosphoric Acid SCHEMBL15054252 | 1.00 | HPRT1 (0.66) | HPRT1POLBCYP3A4POLGPOLA1 | |
| SCHEMBL4715034 | 0.96 | HPRT1 (0.70) | HPRT1CYP3A4PNP | |
| SCHEMBL4713142 | 0.96 | HPRT1 (0.70) | HPRT1CYP3A4PNP | |
| SCHEMBL172846 | 0.96 | HPRT1 (0.70) | HPRT1CYP3A4PNP | |
| SCHEMBL15078152 | 0.90 | POLB (0.68) | HPRT1POLBCYP3A4POLGPOLA1 | |
| SCHEMBL97295 | 0.89 | HPRT1 (0.64) | HPRT1POLBCYP3A4 | |
| SCHEMBL17194157 | 0.89 | HPRT1 (0.64) | HPRT1POLBCYP3A4 | |
| Spermine SCHEMBL20873770 | 0.86 | HPRT1 (0.58) | HPRT1CYP3A4PNP | |
| Spermine SCHEMBL19206966 | 0.86 | HPRT1 (0.58) | HPRT1CYP3A4PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12398162-B2 | Guanine analogs as telomerase substrates and telomere length affectors | GERON CORPORATION (US) | 2025-08-26 | — | — | US | disclosed |
| US-20220306660-A1 | Guanine Analogs as Telomerase Substrates and Telomere Length Affectors | BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT (GB) | 2022-09-29 | — | — | US | disclosed |
| EP-3578563-B1 | GUANINE ANALOGS AS TELOMERASE SUBSTRATES AND TELOMERE LENGTH AFFECTORS | GERON CORP (US) | 2021-04-14 | — | — | EP | disclosed |
| US-20200283461-A1 | Guanine Analogs as Telomerase Substrates and Telomere Length Affectors | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2020-09-10 | — | — | US | disclosed |
| US-10562926-B2 | Guanine analogs as telomerase substrates and telomere length affectors | GERON CORPORATION (US) | 2020-02-18 | — | — | US | disclosed |
| EP-2794624-B1 | GUANINE ANALOGS AS TELOMERASE SUBSTRATES AND TELOMERE LENGTH AFFECTORS | GERON CORP (US) | 2019-05-15 | — | — | EP | disclosed |
| US-20190106447-A1 | Guanine Analogs as Telomerase Substrates and Telomere Length Affectors | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2019-04-11 | — | — | US | disclosed |
| US-10035814-B2 | Guanine analogs as telomerase substrates and telomere length affectors | GERON CORPORATION (US) | 2018-07-31 | — | — | US | disclosed |
| US-20170233419-A1 | Guanine Analogs as Telomerase Substrates and Telomere Length Affectors | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2017-08-17 | — | — | US | disclosed |
| US-9593137-B2 | Guanine analogs as telomerase substrates and telomere length affectors | GERON CORPORATION (US) | 2017-03-14 | — | — | US | disclosed |
| US-20150299232-A1 | GUANINE ANALOGS AS TELOMERASE SUBSTRATES AND TELOMERE LENGTH AFFECTORS | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2015-10-22 | — | — | US | disclosed |
| EP-2794624-A1 | GUANINE ANALOGS AS TELOMERASE SUBSTRATES AND TELOMERE LENGTH AFFECTORS | Geron Corporation (US) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013095684-A1 | GUANINE ANALOGS AS TELOMERASE SUBSTRATES AND TELOMERE LENGTH AFFECTORS | GERON CORPORATION (US) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12398162-B2 | Guanine analogs as telomerase substrates and telomere length affectors | TERT, POT1, TERF2 | HPRT1 38/4885POLB 219/4885CYP3A4 4353/4885 |
| US-10562926-B2 | Guanine analogs as telomerase substrates and telomere length affectors | TERT, POT1, TERF2 | HPRT1 38/4885POLB 219/4885CYP3A4 4353/4885 |
| US-20170233419-A1 | Guanine Analogs as Telomerase Substrates and Telomere Length Affectors | TERT, POT1, TERF2 | HPRT1 38/4885POLB 219/4885CYP3A4 4353/4885 |
| US-10035814-B2 | Guanine analogs as telomerase substrates and telomere length affectors | TERT, POT1, TERF2 | HPRT1 38/4885POLB 219/4885CYP3A4 4353/4885 |
| US-20200283461-A1 | Guanine Analogs as Telomerase Substrates and Telomere Length Affectors | TERT, POT1, TERF2 | HPRT1 38/4885POLB 219/4885CYP3A4 4353/4885 |
| US-20150299232-A1 | GUANINE ANALOGS AS TELOMERASE SUBSTRATES AND TELOMERE LENGTH AFFECTORS | TERT, POT1, TERF2 | HPRT1 41/4885POLB 228/4885CYP3A4 4402/4885 |
| US-20220306660-A1 | Guanine Analogs as Telomerase Substrates and Telomere Length Affectors | TERT, POT1, TERF2 | HPRT1 38/4885POLB 219/4885CYP3A4 4353/4885 |
| US-20190106447-A1 | Guanine Analogs as Telomerase Substrates and Telomere Length Affectors | TERT, POT1, TERF2 | HPRT1 38/4885POLB 219/4885CYP3A4 4353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.